TriSalus Life Sciences (NASDAQ: TLSI) revenue
TriSalus Life Sciences reported revenue of $45.2m for fiscal 2025, 53.4% more than in fiscal 2024 ($29.4m). Since fiscal 2022 its revenue has grown by 264.2%, an average growth of 53.9% a year.
TriSalus Life Sciences has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 4 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $45.2m | +53.4% | −$26.9m | −59.7% |
| 2024 | $29.4m | +59.0% | −$36.2m | −122.9% |
| 2023 | $18.5m | +49.3% | −$54.5m | −294.3% |
| 2022 | $12.4m | — | −$36.4m | −293.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
TriSalus Life Sciences revenue compared with its sector
By revenue for its latest fiscal year, TriSalus Life Sciences ranks 331st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; TriSalus Life Sciences, 53.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 329th | Protagonist Therapeutics | $46.0m | −89.4% |
| 330th | Septerna | $46.0m | 4,174.5% |
| 331st | TriSalus Life Sciences | $45.2m | 53.4% |
| 332nd | Fennec Pharmaceuticals | $44.6m | −6.1% |
| 333rd | Aquestive Therapeutics | $44.5m | −22.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of TriSalus Life Sciences
- How much revenue did TriSalus Life Sciences make in fiscal 2025?
- TriSalus Life Sciences reported revenue of $45.2m for fiscal 2025, compared with $29.4m in fiscal 2024.
- How much has the revenue of TriSalus Life Sciences grown?
- Between fiscal 2022 and fiscal 2025 it went from $12.4m to $45.2m: 264.2% more, an average growth of 53.9% a year.
- What was the best year for revenue at TriSalus Life Sciences?
- Of its last 4 fiscal years, fiscal 2025, with $45.2m.
- Where does TriSalus Life Sciences rank in its sector by revenue?
- It ranks 331st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for TriSalus Life Sciences come from?
- From the annual report (Form 10-K) that TriSalus Life Sciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that TriSalus Life Sciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on TriSalus Life Sciences: the TriSalus Life Sciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.